Figure 1.

Association between baseline uric acid and the risk of the primary composite outcome (worsening heart failure event or cardiovascular death), cardiovascular death, heart failure hospitalization and all‐cause mortality (restricted cubic spline analysis). Model adjusted for randomized treatment (dapagliflozin), age, sex, pulse, systolic blood pressure, body mass index, history of heart failure hospitalization, atrial fibrillation, diabetes status, aetiology of heart failure, left ventricular ejection fraction, New York Heart Association functional classification, N‐terminal pro‐B‐type natriuretic peptide (log), estimated glomerular filtration rate, non‐loop diuretic use, loop diuretic use dose, and use of an angiotensin‐converting enzyme inhibitor, angiotensin receptor blocker or angiotensin receptor–neprilysin inhibitor.